Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Drug Profile

Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Alternative Names: Anti-CD123 CAR-T cells; Anti-CD38 CAR-T cells; Anti-HAVCR2 mAbs - Sorrento; Anti-PD-1 mAbs - Sorrento Therapeutics; Anti-PD-L1 mAbs - Sorrento Therapeutics; Anti-TIM3 mAbs- Sorrento Therapeutics; CAR-T - TNK Therapeutics; CAR-T c-KIT; CAR-T GD3; CAR-T IL13R; STI 1110; STI-A0168; STI-A020X; STI-A050X; STI-A060X; STI-A1010; STI-A1011; STI-A1012; STI-A1110; T-007; T-009

Latest Information Update: 23 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC; Sorrento Therapeutics
  • Developer Sorrento Therapeutics; TNK Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors; Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists; Ganglioside inhibitors; HAVCR2 protein inhibitors; Interleukin 13 expression modulators; Interleukin 13 inhibitors; Interleukin-3 receptor alpha subunit antagonists; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Breast cancer; Cancer; Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
  • 28 Jan 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
  • 28 Jan 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top